应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
01477 欧康维视生物-B
已收盘 05-08 16:08:16
5.220
-0.080
-1.51%
最高
5.350
最低
5.130
成交量
186.73万
今开
5.200
昨收
5.300
日振幅
4.15%
总市值
42.49亿
流通市值
42.49亿
总股本
8.14亿
成交额
974.30万
换手率
0.23%
流通股本
8.14亿
市净率
1.05
ROE
-8.02%
每股收益
-0.42
52周最高
7.410
52周最低
3.620
市盈率
-12.46
股息
0.00
股息收益率
0.00
ROA
-5.29%
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
罗氏宣布投资超20亿人民币 在沪新建生物制药生产基地
美港电讯 · 05:44
罗氏宣布投资超20亿人民币 在沪新建生物制药生产基地
歌礼制药-B：股价涨 3.32% 减肥药催化
和讯网 · 04:42
歌礼制药-B：股价涨 3.32% 减肥药催化
18年无一款商业化产品，现金流仅够撑半年，累亏15亿的瑞博生物受劲敌压制
蓝鲸财经 · 04:20
18年无一款商业化产品，现金流仅够撑半年，累亏15亿的瑞博生物受劲敌压制
歌礼制药-B股价上涨超3% 将公布肥胖症药物早期研究结果
DoNews · 04:06
歌礼制药-B股价上涨超3% 将公布肥胖症药物早期研究结果
港股异动 | 歌礼制药-B(01672)涨超3% 将公布肥胖症候选药物ASC47早期研究结果
智通财经 · 03:30
港股异动 | 歌礼制药-B(01672)涨超3% 将公布肥胖症候选药物ASC47早期研究结果
北京诺华制药有限公司申请III类会议
金融界 · 05-07 21:06
北京诺华制药有限公司申请III类会议
欧康维视生物-B(01477)5月7日回购2000股
智通财经 · 05-07 13:44
欧康维视生物-B(01477)5月7日回购2000股
中证制药指数下跌0.26%，前十大权重包含新和成等
金融界 · 05-07 09:09
中证制药指数下跌0.26%，前十大权重包含新和成等
罗氏格菲妥单抗新适应症在华获批
美港电讯 · 05-07 09:08
罗氏格菲妥单抗新适应症在华获批
欧康维视生物-B05月07日遭主力抛售64.9万元
市场透视 · 05-07 08:15
欧康维视生物-B05月07日遭主力抛售64.9万元
日本盐野义制药将以1500亿日元收购鸟居药品
环球市场播报 · 05-07 06:18
日本盐野义制药将以1500亿日元收购鸟居药品
歌礼制药-B盘中异动 下午盘股价大跌5.02%
市场透视 · 05-07 05:54
歌礼制药-B盘中异动 下午盘股价大跌5.02%
游说团体警告：特朗普药价提案恐致制药业损失1万亿美元
智通财经 · 05-07 03:30
游说团体警告：特朗普药价提案恐致制药业损失1万亿美元
金十数据整理：每日港股市场要闻速递（5月7日 周三）
美港电讯 · 05-07 01:12
金十数据整理：每日港股市场要闻速递（5月7日 周三）
欧康维视生物-B(01477)5月6日斥资5.38万港元回购1万股
智通财经 · 05-06 13:12
欧康维视生物-B(01477)5月6日斥资5.38万港元回购1万股
歌礼制药(01672)将在第32届欧洲肥胖症大会上报告ASC47早期研究成果
金吾财讯 · 05-06 08:51
歌礼制药(01672)将在第32届欧洲肥胖症大会上报告ASC47早期研究成果
歌礼制药：欧洲肥胖症大会报告ASC47研究成果
美港电讯 · 05-06 08:43
歌礼制药：欧洲肥胖症大会报告ASC47研究成果
歌礼制药-B(01672)将在第32届欧洲肥胖症大会报告脂肪靶向、减重不减肌肥胖症候选药物ASC47研究结果
智通财经 · 05-06 08:42
歌礼制药-B(01672)将在第32届欧洲肥胖症大会报告脂肪靶向、减重不减肌肥胖症候选药物ASC47研究结果
歌礼制药-B盘中异动 快速上涨5.04%
市场透视 · 05-06 02:10
歌礼制药-B盘中异动 快速上涨5.04%
大华继显：将石药创新制药股份有限公司评级下调至卖出。
金融界 · 05-05
大华继显：将石药创新制药股份有限公司评级下调至卖出。
加载更多
公司概况
公司名称：
欧康维视生物-B
所属市场：
SEHK
上市日期：
2020-07-10
主营业务：
欧康维视生物是一家主要从事眼科疗法发现、开发及商业化业务的中国控股公司。其主要产品包括OT-401（YUTIQ）、OT-1001（ZERVIATE）、OT-502（DEXYCU）、OT-301（NCX 470）、OT-101和OT-202等。该公司在中国境内开展业务。
发行价格：
14.660
{"stockData":{"symbol":"01477","market":"HK","secType":"STK","nameCN":"欧康维视生物-B","latestPrice":5.22,"timestamp":1746691696013,"preClose":5.3,"halted":0,"volume":1867316,"delay":0,"floatShares":814000000,"shares":814000000,"eps":-0.4187914376986872,"marketStatus":"已收盘","change":-0.08,"latestTime":"05-08 16:08:16","open":5.2,"high":5.35,"low":5.13,"amount":9742976,"amplitude":0.041509,"askPrice":5.22,"askSize":2500,"bidPrice":5.2,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-0.4187914376986872,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1746754200000},"marketStatusCode":5,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":5.3,"openAndCloseTimeList":[[1746667800000,1746676800000],[1746680400000,1746691200000]],"volumeRatio":0.857046,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01477","defaultTab":"news","newsList":[{"id":"2533694063","title":"罗氏宣布投资超20亿人民币 在沪新建生物制药生产基地","url":"https://stock-news.laohu8.com/highlight/detail?id=2533694063","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533694063?lang=zh_cn&edition=full","pubTime":"2025-05-08 13:44","pubTimestamp":1746683049,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1191","BK0028","BK0075","BK0020","600895","BK0059","BK0099","BK0188","BK1161","BK1515","BK0011","01477","BK0012","BK0053","BK0183","BK0190","09939","BK0273","159938","BK1574","BK0184"],"gpt_icon":0},{"id":"2533929301","title":"歌礼制药-B：股价涨 3.32% 减肥药催化","url":"https://stock-news.laohu8.com/highlight/detail?id=2533929301","media":"和讯网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533929301?lang=zh_cn&edition=full","pubTime":"2025-05-08 12:42","pubTimestamp":1746679365,"startTime":"0","endTime":"0","summary":"歌礼制药近日称将在西班牙马拉加举行的第 32 届欧洲肥胖症大会上以口头和壁报形式报告脂肪靶向、减重不减肌的肥胖症候选药物 ASC47 的早期研究。此外，有传闻称“世卫组织计划首次将减肥药纳入基本药物目录以治疗成人肥胖症”。5 月 7 日，世卫组织正式回应，治疗成年肥胖患者的指南正按程序全面制定，预计 2025 年 8 月或 9 月出台最终方案。中信证券此前指，预计后续相关事件将对减肥药板块形成反复催化，有望形成跨年度的主题行情。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505081441239752da30&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505081441239752da30&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","01672","BK1191","01477","BK1574","BK1161"],"gpt_icon":0},{"id":"2533949165","title":"18年无一款商业化产品，现金流仅够撑半年，累亏15亿的瑞博生物受劲敌压制","url":"https://stock-news.laohu8.com/highlight/detail?id=2533949165","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533949165?lang=zh_cn&edition=full","pubTime":"2025-05-08 12:20","pubTimestamp":1746678050,"startTime":"0","endTime":"0","summary":"近日，专注于siRNA疗法的研究并开发小核酸药物的瑞博生物递表港交所，引发了市场对相关创新疗法的广泛探讨。作为备受市场关注的企业之一，瑞博生物当前却尚未有任何商业化的产品，创收主要依靠合作授权收取的费用。弗若斯特沙利文的数据显示，瑞博生物的核心产品RBD4059即靶向FXI的siRNA是全球首款、也是临床开发进展最快的用于治疗血栓性疾病的siRNA药物。从成立至今，累计亏损更是达到了15.22亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/256732","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1588","LU2328871848.SGD","BK1583","LU0307460666.USD","LU1969619763.USD","BK1191","01477","BK1574","06160","LU0588546209.SGD","BK1161","BK1500"],"gpt_icon":0},{"id":"2533294914","title":"歌礼制药-B股价上涨超3% 将公布肥胖症药物早期研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2533294914","media":"DoNews","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533294914?lang=zh_cn&edition=full","pubTime":"2025-05-08 12:06","pubTimestamp":1746677162,"startTime":"0","endTime":"0","summary":"5月8日，歌礼制药-B（01672）午前股价上涨3.32%，报6.54港元。公司将在西班牙马拉加举行的第32届欧洲肥胖症大会上报告肥胖症候选药物ASC47的早期研究结果。ASC47为歌礼自主研发的小分子激动剂，已获FDA批准与司美格鲁肽联用治疗肥胖症。此外，世卫组织计划制定成年肥胖患者治疗指南，预计2025年8月或9月出台。业内人士分析，减肥药板块有望形成跨年度主题行情。免责声明：本文内容由开放的智能模型自动生成，仅供参考。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050812081994f00378&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050812081994f00378&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1515","01477","01672","BK1574","BK1191"],"gpt_icon":0},{"id":"2533943501","title":"港股异动 | 歌礼制药-B(01672)涨超3% 将公布肥胖症候选药物ASC47早期研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2533943501","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533943501?lang=zh_cn&edition=full","pubTime":"2025-05-08 11:30","pubTimestamp":1746675049,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，歌礼制药-B涨超3%，截至发稿，涨3.48%，报6.55港元，成交额743.52万港元。消息面上，歌礼制药近日宣布将在西班牙马拉加举行的第32届欧洲肥胖症大会上以口头和壁报形式报告脂肪靶向、减重不减肌的肥胖症候选药物ASC47的早期研究。美国食品药品监督管理局已批准ASC47与司美格鲁肽联用治疗肥胖症的新药临床试验申请。此外，有传闻称“世卫组织计划首次将减肥药纳入基本药物目录以治疗成人肥胖症”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1290657.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","01477","01672","BK1161","BK1191","BK1515"],"gpt_icon":0},{"id":"2533967937","title":"北京诺华制药有限公司申请III类会议","url":"https://stock-news.laohu8.com/highlight/detail?id=2533967937","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533967937?lang=zh_cn&edition=full","pubTime":"2025-05-08 05:06","pubTimestamp":1746651980,"startTime":"0","endTime":"0","summary":"金融界5月8日消息，据CDE官网沟通交流公示，于5月8日收到北京诺华制药有限公司申请的“III类会议”，当前状态“处理中”。北京诺华制药有限公司，成立于1987年，位于北京市，是一家以从事医药制造业为主的企业。通过天眼查大数据分析，北京诺华制药有限公司参与招投标项目5000次，知识产权方面有商标信息1条，此外企业还拥有行政许可146个。主要股东信息显示，北京诺华制药有限公司由诺华股份有限公司持股100%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/05/08050650209594.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4578","BK4588","IE00B4R5TH58.HKD","LU0070302665.USD","LU0320765489.SGD","IE00B2B36J28.USD","BK4585","IE00BJT1NW94.SGD","LU0211331839.USD","IE00BFTCPJ56.SGD","BK1574","IE0002141913.USD","III","BK4007","BK1191","01477","BK4134","BK4532","LU0208291251.USD","IE0009355771.USD","IE00BJJMRZ35.SGD","NVS"],"gpt_icon":0},{"id":"2533311936","title":"欧康维视生物-B(01477)5月7日回购2000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2533311936","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533311936?lang=zh_cn&edition=full","pubTime":"2025-05-07 21:44","pubTimestamp":1746625454,"startTime":"0","endTime":"0","summary":"智通财经APP讯，欧康维视生物-B(01477)发布公告，于2025年5月7日该公司斥资1.07万港元回购2000股，回购价格为每股5.3675港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1290491.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1574","01477"],"gpt_icon":0},{"id":"2533667218","title":"中证制药指数下跌0.26%，前十大权重包含新和成等","url":"https://stock-news.laohu8.com/highlight/detail?id=2533667218","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533667218?lang=zh_cn&edition=full","pubTime":"2025-05-07 17:09","pubTimestamp":1746608961,"startTime":"0","endTime":"0","summary":"金融界5月7日消息，上证指数高开低走，中证制药指数 下跌0.26%，报2033.01点，成交额167.81亿元。数据统计显示，中证制药指数近一个月下跌1.71%，近三个月上涨6.44%，年至今上涨3.81%。据了解，中证制药指数选取业务涉及中药、化学药和生物药的上市公司证券作为指数样本，以反映制药主题上市公司证券的整体表现。从中证制药指数持仓样本的行业来看，药品制剂占比49.19%、中成药占比30.35%、其他生物药品占比15.42%、原料药占比5.04%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/05/07170950194650.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0187","BK0070","LU0405327494.USD","BK1574","002001","BK1191","BK0028","BK0197","LU0405327148.USD","BK0191","BK0188","BK0239","01477"],"gpt_icon":0},{"id":"2533723116","title":"罗氏格菲妥单抗新适应症在华获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2533723116","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533723116?lang=zh_cn&edition=full","pubTime":"2025-05-07 17:08","pubTimestamp":1746608908,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["01477","BK1574","BK1191"],"gpt_icon":0},{"id":"2533560668","title":"欧康维视生物-B05月07日遭主力抛售64.9万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533560668","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533560668?lang=zh_cn&edition=full","pubTime":"2025-05-07 16:15","pubTimestamp":1746605754,"startTime":"0","endTime":"0","summary":"05月07日, 欧康维视生物-B股价跌1.49%，报收5.30元，成交金额1234.3万元，换手率0.28%，振幅6.13%，量比0.94。欧康维视生物-B今日主力资金净流出64.9万元，上一交易日主力净流出157.7万元。该股近5个交易日下跌1.85%，主力资金累计净流出356.1万元；近20日主力资金累计净流出844.4万元，其中净流出天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507171851a6d62303&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507171851a6d62303&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","01477","BK1574"],"gpt_icon":0},{"id":"2533829629","title":"日本盐野义制药将以1500亿日元收购鸟居药品","url":"https://stock-news.laohu8.com/highlight/detail?id=2533829629","media":"环球市场播报","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533829629?lang=zh_cn&edition=full","pubTime":"2025-05-07 14:18","pubTimestamp":1746598680,"startTime":"0","endTime":"0","summary":"据报道，日本盐野义制药公司计划以约1500亿日元（约合10.1亿美元）的价格收购鸟居药品公司。\n 盐野义将通过一次要约收购从日本烟草公司和其他股东手中收购鸟居药品的股份。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：于健 SF069","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-05-07/doc-inevtimx3656361.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","01477","BK1574"],"gpt_icon":0},{"id":"2533625702","title":"歌礼制药-B盘中异动 下午盘股价大跌5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2533625702","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533625702?lang=zh_cn&edition=full","pubTime":"2025-05-07 13:54","pubTimestamp":1746597287,"startTime":"0","endTime":"0","summary":"2025年05月07日下午盘13时54分，歌礼制药-B股票出现异动，股价大幅下跌5.02%。截至发稿，该股报6.250港元/股，成交量132万股，换手率0.14%，振幅8.36%。机构评级方面，在所有4家参与评级的机构中，75%的券商给予买入建议，25%的券商给予持有建议，无券商给予卖出建议。歌礼制药-B股票所在的生物技术行业中，整体跌幅为4.43%。歌礼制药-B公司简介：歌礼制药有限公司是一家主要从事医药产品研发、生产和销售的投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507135447a474e995&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507135447a474e995&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01672","BK1574","BK1515","01477","BK1161","BK1191"],"gpt_icon":0},{"id":"2533364624","title":"游说团体警告：特朗普药价提案恐致制药业损失1万亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533364624","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533364624?lang=zh_cn&edition=full","pubTime":"2025-05-07 11:30","pubTimestamp":1746588621,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，游说团体警告称，美国总统唐纳德·特朗普的新药品定价提案可能在未来十年内使制药公司损失高达1万亿美元。具体来说，白宫要求众议院共和党人将医疗补助计划中的药品价格与外国支付的价格挂钩，此举将使制药商损失数十亿美元的收入。在特朗普的第二个总统任期内，制药业高管们大多谨慎行事。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1290035.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","01477","BK1574"],"gpt_icon":0},{"id":"2533613097","title":"金十数据整理：每日港股市场要闻速递（5月7日 周三）","url":"https://stock-news.laohu8.com/highlight/detail?id=2533613097","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533613097?lang=zh_cn&edition=full","pubTime":"2025-05-07 09:12","pubTimestamp":1746580378,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK4505","BK4099","09868","EVS.SI","XPEV","BK4526","BK1157","BK1594","07226","BK4551","BK1588","BK1555","01477","LU0997586861.USD","BK1554","YANG","LU0593848301.USD","BK1575","HSTECH","BK1574","00512","BK1154","BK1191","01250","06158","BK4144","BK1161","BK1119","BK4555","01672","BK1610","HSCEI","BK4614","BK1240","ECO","00182","BK1558","BK1539","BK1587","01332","BK1515"],"gpt_icon":1},{"id":"2533639977","title":"欧康维视生物-B(01477)5月6日斥资5.38万港元回购1万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2533639977","media":"智通财经","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533639977?lang=zh_cn&edition=full","pubTime":"2025-05-06 21:12","pubTimestamp":1746537167,"startTime":"0","endTime":"0","summary":"智通财经APP讯，欧康维视生物-B(01477)发布公告，于2025年5月6日，该公司斥资5.38万港元回购1万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1289847.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1574","01477"],"gpt_icon":0},{"id":"2533749915","title":"歌礼制药(01672)将在第32届欧洲肥胖症大会上报告ASC47早期研究成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2533749915","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533749915?lang=zh_cn&edition=full","pubTime":"2025-05-06 16:51","pubTimestamp":1746521494,"startTime":"0","endTime":"0","summary":"金吾财讯 | 歌礼制药 宣布，将在西班牙马拉加举行的第32届欧洲肥胖症大会上以口头和壁报形式报告脂肪靶向、减重不减肌的肥胖症候选药物ASC47的早期研究。ASC47是一款由歌礼自主研发的、脂肪靶向、超长效皮下注射的甲状腺激素受体β选择性小分子激动剂。ASC47具有独特的差异化特性，能够靶向脂肪，从而在脂肪组织中产生剂量依赖性的高药物浓度。美国食品药品监督管理局已批准ASC47与司美格鲁肽联用治疗肥胖症的新药临床试验申请。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/Y2MwODZhYWZmNGQzMDgwOTQyYjU5NWM2YWIxYjEyMTA4MTkwNzMzNjk5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/Y2MwODZhYWZmNGQzMDgwOTQyYjU5NWM2YWIxYjEyMTA4MTkwNzMzNjk5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1958181","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1191","BK1515","01672","01477","BK1574"],"gpt_icon":0},{"id":"2533579335","title":"歌礼制药：欧洲肥胖症大会报告ASC47研究成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2533579335","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533579335?lang=zh_cn&edition=full","pubTime":"2025-05-06 16:43","pubTimestamp":1746520990,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1515","BK1141","01672","01477","BK1191","BK1574","03347","BK1576","BK1583","BK1161"],"gpt_icon":0},{"id":"2533798085","title":"歌礼制药-B(01672)将在第32届欧洲肥胖症大会报告脂肪靶向、减重不减肌肥胖症候选药物ASC47研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2533798085","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533798085?lang=zh_cn&edition=full","pubTime":"2025-05-06 16:42","pubTimestamp":1746520946,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 公布，将在西班牙马拉加举行的第32届欧洲肥胖症大会上以口头和壁报形式报告脂肪靶向、减重不减肌的肥胖症候选药物ASC47的早期研究。ASC47是一款由歌礼自主研发的、脂肪靶向、超长效皮下注射的甲状腺激素受体β选择性小分子激动剂。ASC47具有独特的差异化特性，能够靶向脂肪，从而在脂肪组织中产生剂量依赖性的高药物浓度。美国食品药品监督管理局已批准ASC47与司美格鲁肽联用治疗肥胖症的新药临床试验申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1289585.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1191","BK1161","BK1515","01477","01672"],"gpt_icon":0},{"id":"2533510994","title":"歌礼制药-B盘中异动 快速上涨5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2533510994","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533510994?lang=zh_cn&edition=full","pubTime":"2025-05-06 10:10","pubTimestamp":1746497428,"startTime":"0","endTime":"0","summary":"2025年05月06日早盘10时10分，歌礼制药-B股票出现波动，股价快速上涨5.04%。截至发稿，该股报6.880港元/股，成交量98.9万股，换手率0.10%，振幅5.80%。歌礼制药-B股票所在的生物技术行业中，整体跌幅为0.84%。其相关个股中，科济药业-B、歌礼制药-B、科笛-B涨幅较大，振幅较大的相关个股有百奥赛图-B、诺诚健华、科济药业-B，振幅分别为11.08%、9.20%、7.53%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050610102894ed683f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050610102894ed683f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1161","01477","BK1574","BK1191","01672"],"gpt_icon":0},{"id":"2533327704","title":"大华继显：将石药创新制药股份有限公司评级下调至卖出。","url":"https://stock-news.laohu8.com/highlight/detail?id=2533327704","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533327704?lang=zh_cn&edition=full","pubTime":"2025-05-05 09:37","pubTimestamp":1746409020,"startTime":"0","endTime":"0","summary":"大华继显：将石药创新制药股份有限公司评级下调至卖出。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250505094131974f3b54&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250505094131974f3b54&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01477","01093"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ocumension.com","stockEarnings":[{"period":"1week","weight":-0.0221},{"period":"1month","weight":0.2297},{"period":"3month","weight":0.2589},{"period":"6month","weight":-0.0293},{"period":"1year","weight":-0.273},{"period":"ytd","weight":0.1778}],"compareEarnings":[{"period":"1week","weight":0.0259},{"period":"1month","weight":0.1444},{"period":"3month","weight":0.0862},{"period":"6month","weight":0.0947},{"period":"1year","weight":0.228},{"period":"ytd","weight":0.1312}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"欧康维视生物是一家主要从事眼科疗法发现、开发及商业化业务的中国控股公司。其主要产品包括OT-401（YUTIQ）、OT-1001（ZERVIATE）、OT-502（DEXYCU）、OT-301（NCX 470）、OT-101和OT-202等。该公司在中国境内开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.116968},{"month":2,"riseRate":0.4,"avgChangeRate":-0.049128},{"month":3,"riseRate":0.6,"avgChangeRate":0.058111},{"month":4,"riseRate":0.4,"avgChangeRate":0.017956},{"month":5,"riseRate":0.4,"avgChangeRate":0.049992},{"month":6,"riseRate":0.75,"avgChangeRate":0.066459},{"month":7,"riseRate":0.5,"avgChangeRate":-0.028018},{"month":8,"riseRate":0.4,"avgChangeRate":-0.050881},{"month":9,"riseRate":0.2,"avgChangeRate":-0.087999},{"month":10,"riseRate":0.2,"avgChangeRate":-0.144034},{"month":11,"riseRate":0.4,"avgChangeRate":0.008996},{"month":12,"riseRate":0.6,"avgChangeRate":0.089218}],"exchange":"SEHK","name":"欧康维视生物-B","nameEN":"OCUMENSION-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.4","shortVersion":"4.33.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"欧康维视生物-B,01477,欧康维视生物-B股票,欧康维视生物-B股票老虎,欧康维视生物-B股票老虎国际,欧康维视生物-B行情,欧康维视生物-B股票行情,欧康维视生物-B股价,欧康维视生物-B股市,欧康维视生物-B股票价格,欧康维视生物-B股票交易,欧康维视生物-B股票购买,欧康维视生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}